Scientific Background and Reference Sources
Burstein, H. J., Mangu, P. B., Somerfield, M. R., Schrag, D., Samson, D., Holt, L., . . . Ajani, J. A. (2011). American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol, 29(24), 3328-3330. doi:10.1200/jco.2011.36.0354
Hatok, J., Babusikova, E., Matakova, T., Mistuna, D., Dobrota, D., & Racay, P. (2009). In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med, 9(1), 1-7. doi:10.1007/s10238-008- 0011-3
Herzog, T., & Armstrong, D. (2018). First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer - UpToDate. In S. Vora (Ed.), UpToDate. Waltham, MA: UpToDate, Inc. Retrieved from https://www.uptodate.com/contents/first-line-chemotherapy-foradvanced-stage-iii-or-iv-epithelial-ovarian-fallopian-tubal-and-peritoneal-cancer?search=chemofx&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H250841395.
Hoffman, R. M. (2018). Clinical Correlation of the Histoculture Drug Response Assay in Gastrointestinal Cancer. Methods Mol Biol, 1760, 61-72. doi:10.1007/978-1-4939-7745-1_7
Karam, A. K., Chiang, J. W., Fung, E., Nossov, V., & Karlan, B. Y. (2009). Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol, 114(2), 246-252. doi:10.1016/j.ygyno.2009.02.022
Krivak, T. C., Lele, S., Richard, S., Secord, A. A., Leath, C. A., 3rd, Brower, S. L., . . . Moore, R. G. (2014). A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Am J Obstet Gynecol, 211(1), 68.e61-68. doi:10.1016/j.ajog.2014.02.009
Kwon, H. Y., Kim, I. K., Kang, J., Sohn, S. K., & Lee, K. Y. (2016). In Vitro Adenosine TriphosphateBased Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. Cancer Res Treat, 48(3), 970-977. doi:10.4143/crt.2015.140
Matsuo, K., Eno, M. L., Im, D. D., Rosenshein, N. B., & Sood, A. K. (2010). Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol, 116(1), 61-65. doi:10.1016/j.ygyno.2009.09.018
NCCN. (2017). NCCN Clinical Practice Guidelines in Oncology. NCCN Clinical Practice Guidelines in Oncology. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf NCCN. (2018).
NCCN Clinical Practice Guidelines in Oncology; Ovarian Cancer v 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
Rutherford, T., Orr, J., Jr., Grendys, E., Jr., Edwards, R., Krivak, T. C., Holloway, R., . . . Herzog, T. J. (2013). A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol, 131(2), 362-367. doi:10.1016/j.ygyno.2013.08.009
Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Von Hoff, D. D., & Somerfield, M. R. (2004). American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol, 22(17), 3631-3638. doi:10.1200/jco.2004.05.065
Tatar, B., Boyraz, G., Selçuk, İ., Doğan, A. K., Usubütün, A., & Tuncer, Z. S. (2016). In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays. In J Turk Ger Gynecol Assoc (Vol. 17, pp. 35-40).